Published in Infect Immun on December 01, 1977
Antibody in host defense against mouse pneumonitis agent (murine Chlamydia trachomatis). Infect Immun (1984) 1.47
Oxygen-independent killing by alveolar macrophages. J Exp Med (1986) 1.11
Nonoxidative microbicidal activity in normal human alveolar and peritoneal macrophages. Infect Immun (1987) 1.01
Group B streptococcal type Ia sepsis in mice after intranasal inoculation and the effect of infection on lungs. Infect Immun (1979) 0.87
Kinetics of phagocytosis of Staphylococcus aureus by alveolar and peritoneal macrophages. Infect Immun (1979) 0.85
Comparison of cytotoxic and microbicidal function of bronchoalveolar and peritoneal macrophages. Immunology (1981) 0.82
Adoptive transfer of protection against Trypanosoma cruzi with lymphocytes and macrophages. Infect Immun (1979) 0.81
Schistosoma mansoni larvicidal activity of murine bronchoalveolar lavage cells. Infect Immun (1990) 0.79
Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol (1971) 20.35
SIMPLIFIED MYELOPEROXIDASE STAIN USING BENZIDINE DIHYDROCHLORIDE. Blood (1965) 9.42
The interaction between Toxoplasma gondii and mammalian cells. II. The absence of lysosomal fusion with phagocytic vacuoles containing living parasites. J Exp Med (1972) 8.66
Effect of normal and activated human macrophages on Toxoplasma gondii. J Exp Med (1974) 4.39
Adoptive immunity to intracellular infection. J Immunol (1967) 4.38
The interaction between Toxoplasma gondii and mammalian cells. I. Mechanism of entry and intracellular fate of the parasite. J Exp Med (1972) 4.26
Cellular hypersensitivity and cellular immunity in the pathogensis of tuberculosis: specificity, systemic and local nature, and associated macrophage enzymes. Bacteriol Rev (1968) 4.25
Assessment in vitro of immunity against Toxoplasma gondii. J Exp Med (1975) 3.50
The histogenesis of immunologically committed lymphocytes. Cell Immunol (1972) 3.29
Ocular toxoplasmosis; pathogenesis, diagnosis and treatment. AMA Arch Ophthalmol (1958) 3.19
Inhibition of multiplication of Toxoplasma gondii by human monocytes exposed to T-lymphocyte products. J Exp Med (1975) 3.17
A role for activated macrophages in resistance to infection with Toxoplasma. Infect Immun (1972) 3.12
Toxoplasmosis in the compromised host. Ann Intern Med (1976) 2.96
Receptors for immunoglobulin and complement on human alveolar macrophages. J Immunol (1975) 2.74
Cell-mediated resistance to aerogenic infection of the lung. Am Rev Respir Dis (1971) 2.48
The human alveolar macrophage: isolation, cultivation in vitro, and studies of morphologic and functional characteristics. J Clin Invest (1971) 2.47
Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis (1971) 2.34
Expression of immune mechanisms in the lung. Am Rev Respir Dis (1976) 2.24
Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest (1975) 2.04
Intracellular multiplication of Toxoplasma gondi in adult mammalian macrophages cultivated in vitro. Proc Soc Exp Biol Med (1954) 1.98
Phagocytosis of Cryptococcus neoformans by alveolar macrophages. Infect Immun (1975) 1.83
Toxoplasmosis complicating malignancy. Experience at the National Cancer Institute. Cancer (1968) 1.80
Staining Toxoplasma gondii with fluorescein-labelled antibody. I. The reaction in smears of peritoneal exudate. J Exp Med (1957) 1.54
Cell-mediated immunity against Besnoitia and toxoplasma in specifically and cross-immunized hamsters and in cultures. J Exp Med (1974) 1.51
Specific antibody-dependent killing of Toxoplasma gondii by normal macrophages. Clin Exp Immunol (1976) 1.48
Role for the macrophage in acquired immunity to phylogenetically unrelated intracellular organisms. Antimicrob Agents Chemother (Bethesda) (1968) 1.46
Cell-mediated immunity after bacterial infection of the lower respiratory tract. J Clin Invest (1974) 1.20
Activation of alveolar macrophages after lower respiratory tract infection. J Immunol (1975) 1.18
Disseminated toxoplasmosis in the compromised host. A report of five cases. Arch Intern Med (1974) 1.06
Function of the alveolar macrophage in immunity. J Reticuloendothel Soc (1972) 1.01
Immunological studies on Histoplasma capsulatum. Infect Immun (1975) 0.97
Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science (1988) 7.96
Toxoplasmic encephalitis in AIDS. Clin Infect Dis (1992) 7.64
An enzyme-linked immunosorbent assay for detection of IgM antibodies to Toxoplasma gondii: use for diagnosis of acute acquired toxoplasmosis. J Infect Dis (1980) 5.57
Failure to trigger the oxidative metabolic burst by normal macrophages: possible mechanism for survival of intracellular pathogens. J Exp Med (1980) 5.23
The compromised host and infection. II. Deep fungal infection. J Infect Dis (1969) 4.63
Effect of normal and activated human macrophages on Toxoplasma gondii. J Exp Med (1974) 4.39
AIDS commentary. Toxoplasmic encephalitis. J Infect Dis (1988) 4.14
Toxoplasmosis in pregnancy. Clin Infect Dis (1994) 3.91
Direct agglutination test for diagnosis of Toxoplasma infection: method for increasing sensitivity and specificity. J Clin Microbiol (1980) 3.81
In vitro induction of nonspecific resistance in macrophages by specifically sensitized lymphocytes. Infect Immun (1971) 3.81
Control of carcinogenesis: a possible role for the activated macrophage. Science (1972) 3.69
Interferon: protection of cells infected with an intracellular protozoan (Toxoplasma gondii). Science (1968) 3.65
Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J Immunol (1983) 3.53
Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA (1984) 3.48
Studies on the mechanisms of resistance to phylogenetically diverse intracellular organisms. J Immunol (1969) 3.29
Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics (1980) 3.21
Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J Immunol (1989) 3.20
A role for activated macrophages in resistance to infection with Toxoplasma. Infect Immun (1972) 3.12
IgM antibodies in acute toxoplasmosis. II. Prevalence and significance in acquired cases. J Lab Clin Med (1968) 3.07
Cryptosporidial enteritis in a patient with congenital hypogammaglobulinemia. Hum Pathol (1979) 3.04
Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med (1996) 2.97
Toxoplasmosis in the compromised host. Ann Intern Med (1976) 2.96
False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. J Clin Microbiol (1997) 2.84
Induction of resistance to Toxoplasma gondii in human macrophages by soluble lymphocyte products. J Immunol (1976) 2.79
Dual regulation of resistance against Toxoplasma gondii infection by Lyt-2+ and Lyt-1+, L3T4+ T cells in mice. J Immunol (1988) 2.77
Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory. J Infect Dis (2001) 2.74
Phagocytic and bacterial properties of normal human monocytes. J Clin Invest (1974) 2.65
Immunoglobulin M-immunosorbent agglutination assay for diagnosis of infectious diseases: diagnosis of acute congenital and acquired Toxoplasma infections. J Clin Microbiol (1981) 2.61
Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis (1971) 2.58
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother (1991) 2.56
Toxoplasmosis: the time has come. N Engl J Med (1988) 2.54
Activity of recombinant tumor necrosis factor on Toxoplasma gondii and Trypanosoma cruzi. J Immunol (1986) 2.53
IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis (1990) 2.49
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha. Infect Immun (1994) 2.48
The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice. J Immunol (1990) 2.47
The use of killed vaccines in immunization against an intracellular parasite: Toxoplasma gondii. J Immunol (1972) 2.46
Toxoplasmosis acquired during pregnancy: improved serodiagnosis based on avidity of IgG. J Infect Dis (1993) 2.45
Possible role of macrophage mediated nonspecific cytotoxicity in tumour resistance. Nat New Biol (1972) 2.44
Detection and characterization of membrane antigens of Toxoplasma gondii. J Immunol (1980) 2.43
Infectious complications after cardiac transplantation in man. Ann Intern Med (1971) 2.37
IgM antibodies in acute toxoplasmosis. I. Diagnostic significance in congenital cases and a method for their rapid demonstration. Pediatrics (1968) 2.36
Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J Infect Dis (1971) 2.34
Effect of murine interferon gamma on murine toxoplasmosis. J Infect Dis (1984) 2.27
Antigenemia in recently acquired acute toxoplasmosis. J Infect Dis (1980) 2.20
Differential agglutination test for diagnosis of recently acquired infection with Toxoplasma gondii. J Clin Microbiol (1990) 2.19
Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii. Antimicrob Agents Chemother (1988) 2.16
Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. N Engl J Med (1973) 2.15
Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother (1974) 2.14
Gamma-M-fluorescent treponemal antibody in the diagnosis of congenital syphilis. N Engl J Med (1969) 2.10
Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis (2001) 2.09
Toxoplasmosis in the adult--an overview. N Engl J Med (1978) 2.06
Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis (1996) 2.04
IgM enzyme-linked immunosorbent assay test for the diagnosis of congenital Toxoplasma infection. J Pediatr (1981) 2.04
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis (1991) 2.04
Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis (1981) 2.03
Method for avoiding false-positive results occurring in immunoglobulin M enzyme-linked immunosorbent assays due to presence of both rheumatoid factor and antinuclear antibodies. J Clin Microbiol (1981) 2.03
Tropical fish aquariums. A source of Mycobacterium marinum infections resembling sporotrichosis. JAMA (1970) 2.00
In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol (1985) 2.00
Serologic diagnosis of acute lymphadenopathic toxoplasmosis. J Infect Dis (1980) 1.99
Rapid prenatal diagnosis of congenital Toxoplasma infection by using polymerase chain reaction and amniotic fluid. J Clin Microbiol (1990) 1.95
Dissociation of effector functions in populations of activated macrophages. Nature (1977) 1.95
Analysis of Toxoplasma gondii antigens recognized by human sera obtained before and after acute infection. J Infect Dis (1986) 1.93
The RNA of toxoplasma gondii. Proc Soc Exp Biol Med (1970) 1.93
Synthetic polyanions protect mice against intracellular bacterial infection. Nature (1970) 1.92
Genetic control of murine resistance to Toxoplasma gondii. Infect Immun (1978) 1.91
Immunity and intracellular infection: resistance to bacteria in mice infected with a protozoan. Science (1968) 1.88
A method to evaluate the capacity of monocytes and macrophages to inhibit multiplication of an intracellular pathogen. J Immunol Methods (1979) 1.87
Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.86
Opportunistic invasive fungal infections in patients with leukaemia lymphoma. Clin Haematol (1976) 1.86
Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. The FDA Toxoplasmosis Ad Hoc Working Group. J Clin Microbiol (1997) 1.85
False-positive anti-Toxoplasma fluorescent-antibody tests in patients with antinuclear antibodies. Appl Microbiol (1971) 1.85
Strain-dependent differences in murine susceptibility to toxoplasma. Infect Immun (1976) 1.85
Pulmonary infection in the compromised host: part I. Am Rev Respir Dis (1976) 1.82
The role of thymus-derived lymphocytes in the in vitro activation of macrophages to kill Listeria monocytogenes. J Immunol (1973) 1.82
The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo. Am J Trop Med Hyg (1979) 1.82
Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol (1981) 1.81
Toxoplasmosis in the non-AIDS immunocompromised host. Curr Clin Top Infect Dis (1993) 1.80
Outbreak of central-nervous-system toxoplasmosis in western Europe and North America. Lancet (1983) 1.80
Biology of Toxoplasma gondii. AIDS (1993) 1.79
Comparison of methods for quantitating antigen-specific immunoglobulin M antibody with a reverse enzyme-linked immunosorbent assay. J Clin Microbiol (1983) 1.79
Study of Abbott Toxo IMx system for detection of immunoglobulin G and immunoglobulin M toxoplasma antibodies: value of confirmatory testing for diagnosis of acute toxoplasmosis. J Clin Microbiol (1996) 1.78
Definitive identification of a gene that confers resistance against Toxoplasma cyst burden and encephalitis. Immunology (1995) 1.76
IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol (1995) 1.76
Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol (2000) 1.75
A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice. Immunology (1991) 1.73
Functional and quantitative alterations in T lymphocyte subpopulations in acute toxoplasmosis. J Infect Dis (1984) 1.73
In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother (1992) 1.72
Studies on the regulation of lymphocyte reactivity by normal and activated macrophages. Cell Immunol (1977) 1.70
Studies on the serodiagnosis of toxoplasmic lymphadenitis. Clin Infect Dis (1995) 1.69
Role of specific immunoglobulin E in diagnosis of acute toxoplasma infection and toxoplasmosis. J Clin Microbiol (1993) 1.68
Murine CD8+ cytotoxic T lymphocytes lyse Toxoplasma gondii-infected cells. J Immunol (1991) 1.68
Effect of antibiotics on the immune response. Am J Med (1982) 1.67
Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr (1993) 1.67
Mitogen- and antigen-specific proliferation of T cells in murine toxoplasmosis is inhibited by reactive nitrogen intermediates. Infect Immun (1994) 1.66
Demonstration of Candida precipitins in human sera by counterimmunoelectrophoresis. Lancet (1972) 1.66
Isolation of the encysted form of Toxoplasma gondii from human skeletal muscle and brain. N Engl J Med (1965) 1.64
Toxoplasmic encephalitis in patients with AIDS. Infect Dis Clin North Am (1988) 1.64
Strain typing of Toxoplasma gondii: comparison of antigen-coding and housekeeping genes. J Parasitol (2000) 1.63
Toxoplasmosis in the adult. Bull N Y Acad Med (1974) 1.63